IGFBP2 and non-small cell lung carcinoma: In NSCLC patients, TSA treatment enhances autophagy and reverses the chemoresistance of docetaxel or paclitaxel associated with insulin-like growth factor (IGF) binding protein-2 (IGF-BP2) expression, which has been shown to promote tumorigenesis, metastasis, and cancer stem cell expansion [294].